All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Chagas disease is a major health and economic problem in Latin America, for which no vaccine or appropriate drugs for large-scale public health interventions are yet available \[[@pntd.0005972.ref001]\]. It is caused by the protozoan parasite *Trypanosoma cruzi*, found throughout the Americas in a variety of wild and domestic mammalian reservoirs, and it is usually transmitted by infected blood-sucking triatomine bugs. It is estimated that \~5.7 million people are currently infected with *T*. *cruzi* and that up to 120 million individuals living in endemic areas in Latin America are at risk of infection \[[@pntd.0005972.ref002]\]. Chagas Disease remains the most important parasitic disease in the Western Hemisphere, with an estimated disease burden, as measured by disability-adjusted life-years, that is 7.5 times as great as that of malaria \[[@pntd.0005972.ref002]\]. Increasing travel and immigration have also brought the risk of *T*. *cruzi* infection into non endemic countries \[[@pntd.0005972.ref003]\]. Several efforts have successfully been undertaken to control transmission in Latin America, with a concomitant decrease in the number of acute vector-borne infections \[[@pntd.0005972.ref004]\]. However, humans can also become infected with *T*. *cruzi* through the ingestion of tainted food and fluids, receipt of contaminated blood transfusion or organ transplantation, laboratory accidents, and from mother-to-child during pregnancy/delivery \[[@pntd.0005972.ref001],[@pntd.0005972.ref004]\]. The diagnosis of Chagas disease is challenging because it is often asymptomatic in its acute phase and evolves into a chronic stage in which the disease presents diverse clinical forms \[[@pntd.0005972.ref001]\]. In addition, and due to a major decline in parasitemia during the chronic phase, the detection of *T*. *cruzi* in blood samples by direct examination, hemoculture, or xenodiagnosis is difficult and time-consuming. Several PCR-based procedures have been reported that, although highly specific, present suboptimal sensitivity and require technological expertise and specialized expensive laboratory equipment \[[@pntd.0005972.ref005]\]. In this framework, detection of anti-*T*. *cruzi* antibodies remains the most effective method for demonstrating direct exposure to the parasite \[[@pntd.0005972.ref006]\]. At present, the most widely used serologic methods are indirect hemagglutination assay (IHA), indirect immuno-fluorescence assay (IIF), and enzyme-linked immunosorbent assay (ELISA) using total parasite homogenates or semipurified antigenic fractions \[[@pntd.0005972.ref007]\]. Despite their satisfactory performance, these tests show variations in their reproducibility and reliability that can be attributed to poor standardization of the reagents or intrinsic variability of immune responses in patient populations \[[@pntd.0005972.ref008]--[@pntd.0005972.ref010]\]. In the absence of a single reference test showing 100% specificity and sensitivity, the current guidelines developed by the World Health Organization advise the use of two serologic tests for reaching a conclusive diagnosis. In the case of ambiguous or discordant results, diagnosis using a third technique should be conducted. In addition, there are other still unmet needs and gaps such as access to diagnostics in point-of-care sites for neglected populations \[[@pntd.0005972.ref011],[@pntd.0005972.ref012]\], as well as development of much needed tests for early identification of congenital transmission; rapid assessment of drug treatment efficacy or prognostics tests for disease progression \[[@pntd.0005972.ref010],[@pntd.0005972.ref013]\].

Recombinant DNA and peptide synthesis technologies historically allowed the production and one-step purification of large amounts of *T*. *cruzi* immunodominant antigens \[[@pntd.0005972.ref014]\]. However, several studies showed that the use of single antigens in an assay did not confer the sensitivity required for a diagnostic test \[[@pntd.0005972.ref014],[@pntd.0005972.ref015]\], which prompted the development of tests based on combinations of antigens\[[@pntd.0005972.ref016],[@pntd.0005972.ref017]\], some of which were evaluated in multicenter trials and are commercially available \[[@pntd.0005972.ref018]--[@pntd.0005972.ref020]\]. Synthetic peptides are advantageous for diagnostic applications because they are: i) well defined (ease of quality control), ii) easily produced in large amounts, ii) highly pure and often cost-saving if compared to the production of natural or recombinant antigens *in vitro* \[[@pntd.0005972.ref021]\]; and iv) also chemically stable (can be stored lyophilized or dessicated and tend to be stable for several years).

Short synthetic peptides spanning linear B-cell epitopes can also be used in serodiagnostic applications to increase specificity (that is, decrease the number of false positives) by replacing the use of whole protein antigens, therefore avoiding the display of unnecessary sequences that may lead to 'false positive' results. Specificity is a critical issue in serodiagnosis of Chagas Disease, where most reagents present cross-reactivity against other co-endemic parasites such as *Leishmania spp*. \[[@pntd.0005972.ref018],[@pntd.0005972.ref021]\]. Peptide sensitivity, on the other hand can be increased using more densely presented immunoreactive epitopes (i.e. by creating a synthetic poly-epitopic molecule) or by combining multiple antigenic peptides in a single multiplex-assay \[[@pntd.0005972.ref021]--[@pntd.0005972.ref023]\]. A number of studies described the use of short peptides, containing either one or several epitopes for diagnosis of Chagas disease and other infectious diseases \[[@pntd.0005972.ref023]--[@pntd.0005972.ref034]\].

Recently, we have prioritized a number of candidate diagnostic targets from the genome of *T*. *cruzi* \[[@pntd.0005972.ref035]\] and conducted a large-scale screening of parasite B-cell linear epitopes using high-density peptide microarrays \[[@pntd.0005972.ref036]\]. This approach led to the identification of several hundred novel epitopes associated to chronic Chagas Disease, from which we selected 30 for further characterization. In this paper, we describe their diagnostic evaluation in ELISA format using a large panel of serum samples. In addition, and following an *in silico*-guided antigen combination strategy, we developed a proof-of-principle diagnostic kit based on these reactive peptides.

Materials and methods {#sec002}
=====================

Peptide selection {#sec003}
-----------------

More than 2,000 candidate serodiagnostic peptides were previously identified by our group using a T. cruzi/Chagas HD peptide microarray \[[@pntd.0005972.ref036]\]. To guide the selection of a subset of peptides for further serological characterization, a filtering strategy was conducted, as follows. First, peptides with serodiagnostic potential (high signal-to-noise ratio in the microarray experiments) were mapped to 187 distinct antigenic protein regions (stretches of adjacent peptides in a protein sequence). These antigenic regions may contain either a single B-cell linear epitope or, in some cases, a limited number of partially overlapping epitopes \[[@pntd.0005972.ref037]\]. Next, antigenic regions were grouped into clusters of sequence-related peptides, in such a way that peptide sequences sharing stretches of 7 or more identical amino acids were put into the same cluster. We reasoned that peptides within a cluster may be both sequence and also likely antigenically related, whereas peptides from different clusters may likely represent the targets of different antibody specificities. From each cluster only a single antigenic region was kept (the one with highest microarray average seroreactivity). After this filter 95 unique antigenic regions were obtained (non-redundant, non-similar). From this set we selected 30 peptides from the top of the ranking for further characterization (the most reactive 15-mer from each antigenic region was selected). To minimize possible bias in our selection, the number of selected peptides from overrepresented sequences such as those from the mucin-associated surface protein (MASP) family \[[@pntd.0005972.ref038]\] and from previously known antigens with mapped epitopes \[[@pntd.0005972.ref024],[@pntd.0005972.ref039]--[@pntd.0005972.ref043]\] was limited to 3 and 4, respectively. Sequence and features of our final set of synthetic peptides is summarized in [Table 1](#pntd.0005972.t001){ref-type="table"}.

10.1371/journal.pntd.0005972.t001

###### Sequence and features of synthetic peptides evaluated in this work.

Bibliographic references are provided for the most relevant publication where the corresponding epitope has been mapped, or the protein has been validated as a human antigen.

![](pntd.0005972.t001){#pntd.0005972.t001g}

  Peptide   Protein            Description                                    Peptide sequence     Reference
  --------- ------------------ ---------------------------------------------- -------------------- ----------------------------
  **p1**    TcCLB.507071.20    mucin-associated surface protein (MASP)        `LQVAGIKTTTATTGDS`   This work
  **p2**    TcCLB.506401.320   60S ribosomal protein L7a, antigenic protein   `AKPAAKPAAKPAAKP`    \[[@pntd.0005972.ref035]\]
  **p3**    TcCLB.506973.30    mucin-associated surface protein (MASP)        `EKQQQSDEAQVQQHQ`    This work
  **p4**    TcCLB.511727.290   RNA-binding protein                            `PASKPAAKPAAKAPA`    This work
  **p5**    TcCLB.507083.109   hypothetical protein, conserved                `WFEREVDGHDFIREH`    This work
  **p6**    TcCLB.507071.170   mucin TcMUCII                                  `TTNAPSRLREIDGSL`    \[[@pntd.0005972.ref044]\]
  **p7**    TcCLB.509793.50    hypothetical protein, conserved                `KLGKSVGLTAALSPR`    This work
  **p8**    TcCLB.510101.430   40S ribosomal protein S21                      `GRDAPQARKQQGRNE`    This work
  **p9**    TcCLB.511679.10    mucin TcSMUGS                                  `EGQYDAADVEAGDGP`    This work
  **p10**   TcCLB.506391.30    EF-hand protein 5                              `LMTREVDDTMADELR`    \[[@pntd.0005972.ref020]\]
  **p11**   TcCLB.511529.80    kinetoplast DNA-associated protein             `ALRVSPYSIFLQELA`    This work
  **p12**   TcCLB.511633.79    microtubule-associated protein                 `EEEEDVGPRHVDPDH`    \[[@pntd.0005972.ref045]\]
  **p13**   TcCLB.506961.25    trans-sialidase                                `DSAKGKATGSSAGED`    This work
  **p14**   TcCLB.511287.120   40S ribosomal protein S2                       `RDPTDEHSDFLTMGS`    This work
  **p15**   TcCLB.506563.40    beta tubulin                                   `PTGTYQGDSDLQLER`    This work
  **p16**   TcCLB.504159.10    hypothetical protein, antigenic protein n126   `TSAPAAGGFGSATTT`    \[[@pntd.0005972.ref035]\]
  **p17**   TcCLB.511633.79    microtubule-associated protein                 `PTTSARRLRTRTGPL`    \[[@pntd.0005972.ref045]\]
  **p18**   TcCLB.510421.330   hypothetical protein, conserved                `ILDRFLAAAMDKVFT`    This work
  **p19**   TcCLB.506989.190   heat shock protein 90, putative (LPG3)         `PVDNDGDESSDKEDA`    This work
  **p20**   TcCLB.511633.79    microtubule-associated protein                 `VDPSAYKRALPLEEQ`    \[[@pntd.0005972.ref045]\]
  **p21**   TcCLB.509157.120   hypothetical protein, conserved                `SGAVPEGEEYPTEAE`    \[[@pntd.0005972.ref046]\]
  **p22**   TcCLB.507071.100   mucin-associated surface protein (MASP)        `SEREDDEENDEEEDG`    This work
  **p23**   TcCLB.511727.290   RNA-binding protein                            `GAAKAPAPKAAAPAP`    This work
  **p24**   TcCLB.511671.50    hypothetical protein, antigenic protein n96    `AKPPAESPFKSVFGA`    \[[@pntd.0005972.ref035]\]
  **pc1**   TcCLB.508831.140   B13 / Ag2 / CA-2 / PEP2                        `APFGQAAAGDKPSPF`    \[[@pntd.0005972.ref041]\]
  **pc2**   TcCLB.509149.40    Ribo L19                                       `AAAPAKAAAAPAKAA`    \[[@pntd.0005972.ref024]\]
  **pc3**   TcCLB.505975.20    TcD / Ag13                                     `EPKSAEPKPAEPKSA`    \[[@pntd.0005972.ref045]\]
  **pc4**   X57235             Trans-sialidase (SAPA)                         `TPADSSAHSTPSTPA`    \[[@pntd.0005972.ref043]\]

Peptides in [Table 1](#pntd.0005972.t001){ref-type="table"} were synthesized and used in ELISA assays as described below (see also [Results](#sec008){ref-type="sec"}) to screen for reactivity against Chagas positive and negative (control) samples. Once we obtained a first matrix of reactivity of peptides vs individual serum samples, we applied the EpiSelect algorithm to guide the selection of sets of peptides for the formulation of multiepitope assays. Implementation of the algorithm has been described \[[@pntd.0005972.ref047]\], but briefly the algorithm aims to find the smallest selection of peptides (epitopes) that in concert maximizes the coverage (reactivity) against a given set of subjects. The input to the algorithm was the matrix of peptide reactivity values determined by ELISA, encoded as z-scores defined as the number of standard deviations above background. Positive peptides were defined using a z-score threshold of 3.

Synthetic peptides and BSA conjugation {#sec004}
--------------------------------------

Synthetic peptides were purchased from Schafer-N (Copenhagen, Denmark). Peptides were synthesized using standard FMOC chemistry, purified by HPLC (\> 90% purity) and characterized by mass spectroscopy. A C-terminal cysteine residue was included in all peptides for conjugation to maleimide-activated BSA. An additional amino acid residue (leucine) was added at the N-terminus of peptide p1, to avoid the partial deamination associated with an N-terminal glutamine \[[@pntd.0005972.ref048]\]. Lyophilized peptides were resuspended in sterile-filtered water (Sigma Product w3500), and conjugated to maleimide-activated BSA (mBSA, Sigma-Aldrich Product B7542) according to the manufacturer's protocol, using a molar ratio of 35:1 peptide to mBSA \[[@pntd.0005972.ref049]\]. Peptide-mBSA conjugates were stored in 50% glycerol at -20°C until use. Peptides that failed to solubilize under these conditions were discarded for the analysis.

Human serum samples, samples size and error estimation {#sec005}
------------------------------------------------------

Human serum samples from *T*. *cruzi*-infected patients used in this study were obtained from the Laboratorio de Enfermedad de Chagas, Hospital de Niños \"Dr. Ricardo Gutierrez\" (HNRG, Buenos Aires, Argentina) (n = 80). Human serum samples from patients with American Tegumentary Leishmaniasis (ATL) used in this study were obtained from the Instituto de Patología Experimental, Universidad Nacional de Salta (IPE, Salta, Argentina) (n = 19). All procedures were approved by the research and teaching committee and the bioethics committee of both institutions, and followed the Declaration of Helsinki Principles. Written informed consent was obtained from all individuals (or from their legal representatives), and all samples were decoded and de-identified before they were provided for research purposes. Chagasic patients were in the asympomatic chronic stage of the disease without cardiac or gastrointestinal compromise (age range: 11 to 51 years old, median age: 20). Serum samples were collected from clotted blood obtained by venipuncture and analyzed for *T*. *cruzi*-specific antibodies with the following commercially available kits: ELISA using total parasite homogenate (Wiener lab, Argentina) and IHA (Polychaco, Buenos Aires, Argentina). ATL patients were diagnosed using a combination of techniques: direct observation of parasites (amastigotes) on smears of dermal scrapings; a test of delayed-type hypersensitivity (Montenegro skin test); and a clinical assessment (see \[[@pntd.0005972.ref050]\]). The negative panel was composed of samples from healthy, non-infected individuals that gave negative results in the aforementioned tests, and were obtained either from the blood bank "Fundación Hemocentro Buenos Aires" (FHBA Buenos Aires, Argentina) (n = 82) or from IPE (n = 18). Samples from FHBA were also negative for HIV, Hepatitis B, Hepatitis C, HTLV I and II, *Treponema pallidum* (syphilis) and for Brucelosis (Huddlesson test).

To calculate the minimum sample size required to estimate sensitivity or specificity for a specified interval of confidence and precision under a normal approximation, we used the following formula: $$n = \frac{Z^{2}\mspace{9mu}\hat{P}\ {({1 - \hat{P}})}}{d^{2}}$$ Where Z is the z-score from a standard normal distribution (e.g. 1.96 for a 95% confidence interval), $\hat{P}$ is the pre-determined (guess) value of sensitivity (or specificity) based on previous experience/judgment, and ***d*** is the required precision \[[@pntd.0005972.ref051]\]. Therefore, for **Z** = 1,96 (95% CI), $\hat{\mathbf{P}}$ = 0.99, and ***d*** = 0.05 (5% error), the estimated sample size is 73. Therefore 73 is the minimum number of Chagas positive samples (to estimate sensitivity) and Chagas negative samples (to estimate specificity).

ELISA assays and statistical analysis {#sec006}
-------------------------------------

Microplates containing 96 or 384-wells (Thermo Scientific ImmunoPlates, MaxiSorp) were coated overnight at 4°C with 100 ng/well of peptide-mBSA or with different peptide mixtures (80 ng/well of each one) in PBS pH 7.4. Blank signal was determined using mBSA-coated wells. After 4 washings with TBS-T (50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.05% (v/v) Tween20), the plates were blocked for 1 h at room temperature with 100 μl/well of assay buffer (3% (w/v) skimmed milk in TBS-T). The plates were washed and incubated for 1 h with human sera diluted as indicated (1:100 or 1:10) in assay buffer at room temperature. Optimization of the assay conditions was performed by a checkerboard titration analysis using 10 ng or 80 ng of peptide-mBSA, and different dilutions of secondary antibody (peroxidase-conjugated goat anti-human IgG antibodies (Sigma-Aldrich, St Louis, MO) (1:5,000; 1:10,000; 1:20,000 and 1:80,000). After washings, 100 μl of secondary antibody diluted as indicated (1:10,000 for assays using a single peptide per well, or 1:80,000 for multiepitope assays) in assay buffer were added to each well and incubated for 1 h at room temperature. Following additional washings with TBS-T, the reaction was developed with tetramethylbenzidine for 15 min (TMB, Sigma-Aldrich, St Louis, MO) and stopped by addition of 0.2 M sulphuric acid. Absorbance values were measured at 450 nm in a microplate absorbance reader (FilterMax F5 Multimode, Molecular Devices, Sunnyvale, CA, USA). All serum samples were tested in duplicate. Values were averaged and blank-corrected.

Data analysis {#sec007}
-------------

The same 16 serum samples from healthy blood donors were tested in each ELISA plate. The cut-off value was determined for each peptide and for each plate using the mean of the control blood donor samples plus 3 SD (the cut-off was set accounting for multiple-hypothesis testing). For each peptide or peptide mixture, standardized reactivity scores (z-scores) and the diagnostic analytical characteristics of sensitivity, specificity and AUC (Area under the ROC--Receiver Operating Characteristic--curve, as a performance metric) were calculated. Reagent sensitivity was calculated as the number of positive subjects (i.e. infected patients samples that were reactive against a particular peptide) over the total number of infected subjects tested; specificity was calculated as the number of negative subjects (non-infected control subjects that were seronegative against a particular peptide) over the total number of non-infected control subjects tested and AUC was calculated using the from the z-scores of infected subjects and non-infected subjects. For receiver operating characteristic (ROC) analyses \[[@pntd.0005972.ref052]\], the results were expressed as the percentage of reactivity of the mean absorbance at 450 nm of the positive reference control serum included in each assay run. The Mann-Whitney test and ROC analysis were performed using the GraphPad Prism software (version 6 for OSX; San Diego, CA, USA) or ROCR R package \[[@pntd.0005972.ref053]\].

Results {#sec008}
=======

Diagnostic performance of selected peptides in ELISA format {#sec009}
-----------------------------------------------------------

Based on our previous screening of serodiagnostic peptides for Chagas Disease using HD peptide microarrays \[[@pntd.0005972.ref036]\], 30 peptides were selected for further serological characterization and downstream validation. The strategy for selection of these peptides is outlined in [Fig 1](#pntd.0005972.g001){ref-type="fig"} (see also [Methods](#sec002){ref-type="sec"}), and essentially was guided to select a non-redundant set of peptides showing the highest antibody-binding signal in any array. After removing 3 peptides that showed solubility problems, the remaining 27 peptides were coupled to a carrier protein (mBSA) and assayed in ELISA format against a sera panel of 62 chronically infected Chagasic patients and 16 healthy controls. Initially, all human sera were tested at 1:100 dilutions. The panel of peptides included 16 peptides corresponding to previously uncharacterized *T*. *cruzi* proteins (novel antigens) that emerged during our screening \[[@pntd.0005972.ref036]\], 7 peptides representing novel epitopes in previously characterized B-cell antigens and 4 peptides corresponding to previously known linear B-cell epitopes, which were used as positive controls (see [Table 1](#pntd.0005972.t001){ref-type="table"} and [S1 Fig](#pntd.0005972.s001){ref-type="supplementary-material"}). We also included in our panel an additional peptide (p17) as an internal negative control. Although belonging to a validated *T*. *cruzi* antigen \[[@pntd.0005972.ref054]\], this peptide was derived from a protein region that showed consistently very low signal in all microarray replicates.

![Flowchart showing the strategy for peptide selection.](pntd.0005972.g001){#pntd.0005972.g001}

Diagnostic sensitivity, specificity and AUC values for each peptide are shown in [Table 2](#pntd.0005972.t002){ref-type="table"} (complete data available in [S1 Table](#pntd.0005972.s004){ref-type="supplementary-material"}). The diversity of reactivities in the collection of sera samples when assayed against individual peptides is also evident when visualizing the data in the form of a heatmap plot (available in [S2 Fig](#pntd.0005972.s002){ref-type="supplementary-material"}). As shown, promising diagnostic performances were observed for most of the assayed peptides. Sensitivity values ranged from 30--92% (\>50% in 22 out of 27), and specificity values were extremely high, which is consistent with our screening strategy \[[@pntd.0005972.ref036]\]. In this context, it is worth noting that sensitivity values of all individual *T*. *cruzi* antigens described so far and proposed and/or included in serodiagnostic tests ranged from 80--99% \[[@pntd.0005972.ref014]\].

10.1371/journal.pntd.0005972.t002

###### Diagnostic performance of selected peptides in ELISA format.

Peptides are sorted per decreasing sensitivity.

![](pntd.0005972.t002){#pntd.0005972.t002g}

  Peptide   Avg signal (pepchips)   Sensitivity (n = 62)   Specificity      ROC AUC
  --------- ----------------------- ---------------------- ---------------- ---------
  **pc1**   46,23                   91,98                  98.36 (n = 61)   0,99
  **pc2**   35,22                   90,31                  96.72 (n = 61)   0,98
  **p7**    17,19                   84,06                  96.72 (n = 61)   0,94
  **p11**   13,43                   84,06                  95.1 (n = 61)    0,96
  **p16**   10,89                   83,85                  98.36 (n = 61)   0,94
  **p1**    64,57                   80,94                  98.36 (n = 61)   0,94
  **p19**   7,39                    80,94                  95.1 (n = 61)    0,95
  **p5**    26,15                   80,63                  98.36 (n = 61)   0,96
  **pc3**   13,66                   78,96                  100 (n = 61)     0,97
  **pc4**   0,08                    77,08                  95.1 (n = 61)    0,94
  **p12**   11,73                   76,15                  96.72 (n = 61)   0,94
  **p24**   4,45                    74,17                  100 (n = 61)     0,95
  **p6**    23,56                   69,06                  98.36 (n = 61)   0,9
  **p21**   6,87                    65,94                  95.1 (n = 61)    0,88
  **p18**   7,63                    64,79                  96.72 (n = 61)   0,91
  **p13**   11,53                   60,42                  96.72 (n = 61)   0,88
  **p15**   11,1                    59,58                  100 (n = 16)     0,81
  **p2**    50,61                   57,81                  100 (n = 16)     0,88
  **p4**    26,52                   56,04                  100 (n = 16)     0,88
  **p10**   13,78                   54,79                  100 (n = 16)     0,88
  **p3**    31,06                   53,65                  100 (n = 16)     0,8
  **p20**   4,3                     50,1                   100 (n = 16)     0,83
  **p8**    16,7                    45,83                  93,8 (n = 16)    0,76
  **p14**   11,22                   45,73                  93,8 (n = 16)    0,76
  **p22**   6,65                    32,4                   100 (n = 16)     0,72
  **p23**   5,85                    30,42                  100 (n = 16)     0,77
  **p9**    15,68                   29,06                  93,8 (n = 16)    0,73
  **p17**   0                       3,23                   100 (n = 16)     ND

Overall, and as previously reported for the TSSA antigen \[[@pntd.0005972.ref037]\], a strong correlation between assays in the standard ELISA format and in microarray format was observed for each peptide ([Table 1](#pntd.0005972.t001){ref-type="table"}), thus providing additional validation and support for the use of HD-peptide arrays for discovery of new serology-based biomarkers.

Extended evaluation of diagnostic specificities of top-ranked peptides {#sec010}
----------------------------------------------------------------------

We further evaluated the diagnostic specificity of the 16 best performing peptides (see [Table 1](#pntd.0005972.t001){ref-type="table"}) by using an extended panel of 61 control sera obtained from healthy subjects (Chagas-negative samples). As before, individual peptides coupled to mBSA were assayed in ELISA format. Diagnostic specificities and ROC-AUC were re-calculated for each peptide (top entries in [Table 2](#pntd.0005972.t002){ref-type="table"}). The average specificity was 97.23% and in all cases specificities \> 95% were observed. Notably, most of the positive responses observed in this expanded set of Chagas-negative samples correspond to only 3 of the 61 sera samples tested. These samples (also negative for the highly-sensitive trans-sialidase inhibition assay \[[@pntd.0005972.ref055]\]) were highly reactive against more than half of the peptides (12, 11 and 9 peptides each, see [S1 Table](#pntd.0005972.s004){ref-type="supplementary-material"} in the 'Additional negative sera' section), suggesting a broad and yet-to-be explained cross-recognition towards *T*. *cruzi*-derived sequences. If these Chagas-negative serum samples were removed, specificity values of our peptides would increase up to an average 98.5%.

A novel multiepitope diagnostic method for Chagas Disease {#sec011}
---------------------------------------------------------

Based on the results described above, we undertook an *in silico*-guided approach to design a multiplex assay with improved diagnostic performance. Using ELISA data from individual peptides, we applied the EpiSelect algorithm \[[@pntd.0005972.ref047]\] (see [Methods](#sec002){ref-type="sec"}) to identify several optimal (minimal) virtual peptide sets that in concert provided maximal coverage of the analyzed subjects. This analysis was performed after removing data from the 9 serum samples that were previously used in microarray experiments, to avoid optimistically biased results. The analysis performed on the tested peptides and 53 Chagas-positive subjects showed that 3 peptides were enough to reach a theoretical sensitivity of 100% ([Fig 2](#pntd.0005972.g002){ref-type="fig"}). Data used for this analysis is available in [S1 Table](#pntd.0005972.s004){ref-type="supplementary-material"}. The optimal set was composed by peptides {pc1, pc2, and p6}, resulting in an average of 2.51 reactive peptides per subject, closely followed by the peptide set {pc2, p11, and p6} with an average of 2.43 reactive peptides per subject. The reactivity patterns for these sets are shown in [Fig 2](#pntd.0005972.g002){ref-type="fig"} and [S1 Table](#pntd.0005972.s004){ref-type="supplementary-material"}. Interestingly, at least 1 of the 3 novel peptides p6 (as in [Fig 2](#pntd.0005972.g002){ref-type="fig"}), p2 or p8 (alternatives) would be required to achieve a sensitivity of 100% with a 100% specificity (see also [S1 Table](#pntd.0005972.s004){ref-type="supplementary-material"}).

![Reactivity pattern of example optimal peptide subsets.\
Two peptide combinations were created using the EpiSelect algorithm to achieve a theoretical 100% sensitivity, based on data from the individual assays in [S1 Table](#pntd.0005972.s004){ref-type="supplementary-material"} (53 Chagas positive samples, 27 peptides). The figure shows positive (green) and negative (red) results for each combination of peptide and subject. The cumulative sensitivity is also indicated. For each set, the bottom row displays the cumulative number of positive results for each subject.](pntd.0005972.g002){#pntd.0005972.g002}

Other peptides such as p5, p7, p11, p12, p16, p19 and p24 also displayed excellent diagnostic characteristics, with individual high sensitivity (\> 70%) and specificity (up to 95%). Hence, these peptides can be eventually incorporated into the multiplex design to increase its robustness (for example, to increase the number of reactive peptides per subject).

Based on these analyses, we prepared and tested a number of multi-epitope peptide combinations in ELISA format against an extended panel of sera from chagasic (positive) and healthy (negative) subjects. One such combination {pc1, pc2, pc3, p6, p13}, was tested against 22 positive and 24 negative serum samples and gave a diagnostic sensitivity of 72.7% and a specificity of 91.7%. Following the same methodology ([S1 Table](#pntd.0005972.s004){ref-type="supplementary-material"}), we tested a slightly different formulation of peptides (pc1, pc2, p6, p7 and p24) against an increased number of sera samples (53 Chagas-positive and 31 Chagas-negative) obtaining an improved performance, with a sensitivity of 92.45% and a specificity of 93.55%.

Finally, with the aim of obtaining a peptide combination with enhanced robustness, we re-analyzed the reactivity profile of each individual serum sample ([S1 Table](#pntd.0005972.s004){ref-type="supplementary-material"}) against our panel of peptides, and identified a few Chagas positive subjects that gave low or even negative reactivity to many peptides. From this analysis, we identified peptides that would theoretically maximize the sensitivity of the multiplex assay, despite not showing the best possible coverage of our subject (sera) collection. Thus, we arrived at a high performance multi-epitope formulation of seven peptides {pc1, pc2, pc3, p6, p7, p13, and p24}. To validate this final formulation, we increased the amount of coated peptide to 80 ng of each peptide per well and the serum concentration to 1:10. After these modifications, the performance of this formulation, when tested against 82 Chagas-positive and 80 Chagas-negative sera samples gave a sensitivity of 96.34% and a specificity of 100%, with an AUC value of 0.9974 ([Fig 3](#pntd.0005972.g003){ref-type="fig"}).

![Diagnostic performance of the final multiepitope formulation.\
**A)** Scatter plot showing the distribution of ELISA raw signal obtained from sera samples of Chagas-positive (green circles) and healthy subjects (red squares). Statistical significance (\*) p\<0.0001, Mann-Whitney test. Green empty circles in the left scatter plot represent those within 3 standard deviations of the average signal of healthy controls. **B)** Receiver Operating Characteristic curve and statistics for the analysis. **C)** Scatter plot showing the distribution of ELISA raw signal obtained from Leishmaniasis-positive (green cirles) and Leishmaniasis-negative subjects from the same co-endemic region (red squares). Empty circles represent data points that fall at \>3 SD from their respective distributions.](pntd.0005972.g003){#pntd.0005972.g003}

We have also assessed the performance of this multiepitope formulation against a panel of 19 sera from subjects with positive diagnosis for American Tegumentary Leishmaniasis (see [Methods](#sec002){ref-type="sec"}), and another 18 negative (control sera) from the same endemic region. Only a single (negative) subject gave a positive response in our multiepitope assay ([Fig 3C](#pntd.0005972.g003){ref-type="fig"}). Except for this case, the observed absorbance in the ELISA assays was nil. The specificity of the multiepitope formulation for this panel was 97.30%, with an overall specificity (considering all negative samples from all panels) of 99.15%. [Table 3](#pntd.0005972.t003){ref-type="table"} summarizes the performance of this combination of peptides. This therefore represents a highly promising novel multiepitope formulation for the diagnosis of Chagas Disease.

10.1371/journal.pntd.0005972.t003

###### Summary of performance of the final multiepitope combination.

![](pntd.0005972.t003){#pntd.0005972.t003g}

  Multi-epitope combination              pc1, pc2, pc3 + p6, p7, p13, p24
  -------------------------------------- ----------------------------------
  **Sensitivity (True Positive Rate)**   96.34%
  **Specificity (True Negative Rate)**   99.15%
  **Positive Predictive Value**          98.75%
  **Negative Predictive Value**          97.47%

Discussion {#sec012}
==========

Serological diagnostics methods for infectious diseases have usually evolved from first-generation lysate-based reagents. Through time, more defined formulations of diagnostic reagents have followed. Second-generation diagnostic kits based on purified antigenic fractions or third-generation kits based on recombinant proteins are now in widespread use. To develop new diagnostic tools that are simple and have few manipulation steps, one of the central aspects that currently limits the suitability of diagnostic kits is the need to produce, prepare and purify the antigens, along with the corresponding quality control. Short synthetic peptides can be produced cheaply in large quantities, and are chemically stable and amenable for long-term storage. Synthetic peptides have been already tested in a wide range of diagnostic applications and proved valuable for diagnosis of viral, bacterial, parasitic and autoimmune diseases \[[@pntd.0005972.ref021],[@pntd.0005972.ref030]--[@pntd.0005972.ref034]\]. Therefore, fourth-generation diagnostic kits based on well-defined peptidic antigens are now within reach.

Here we present a next-generation diagnostic formulation for Chagas Disease based on short peptides. Significant efforts have been invested by various groups over time to identify and test antigenic peptides for serodiagnosis of Chagas Disease, some of which displayed promising analytical characteristics. For example, peptides Ag2/B13/Pep2, TcD/Ag13, TcE and TcLo1.2, have been combined to create a multi-epitope recombinant neo-protein of excellent performance \[[@pntd.0005972.ref024]\], and peptides from the cytoplasmic repetitive antigen (CRA)/Ag30 and flagellar repetitive antigen (FRA)/Ag1 \[[@pntd.0005972.ref054]\] have been recently shown to present good specificity and sensitivity \[[@pntd.0005972.ref056]\].

The advent of novel high-throughput approaches spawned by the post-genomic era is starting to impact on the discovery of new biomarkers and the development of diagnostic tools for a number of important pathogens \[[@pntd.0005972.ref010]\]. We have recently showed the utility of a fast approach to screen for new *T*. *cruzi* antigens that is based on high-density peptide microarrays \[[@pntd.0005972.ref036]\]. The advantage of this platform is that it allows to identify antigens and at the same time obtain a fine mapping of their linear epitopes. Using this strategy we have identified and mapped the epitopes of \>90 novel *T. Cruzi* antigens \[[@pntd.0005972.ref036]\].

As a followup of this first screening for peptidic antigens, we provide here an extensive serological characterization of 27 peptides, 18 of which represent novel epitopes that were mapped using our strategy, or represent recently discovered antigens but for which no fine epitope mapping was yet available (see [Table 1](#pntd.0005972.t001){ref-type="table"}). For example, even though the trans-sialidase/SAPA antigen (accession number X57235, TcCLB.509495.30 is the most similar genome locus tag) has been known for quite some time, peptide p13 (also annotated as 'trans-sialidase') is not derived from the originally described antigen, but from another member of the superfamily (TcCLB.506961.25) with only 29% identity to the original trans-sialidase/SAPA. Therefore, p13 is a new/novel antigen and epitope that bear no resemblance to any of the mapped epitopes already described \[[@pntd.0005972.ref043],[@pntd.0005972.ref057]\]. Similarly, even though the proteins encoded by the genes TcCLB.511633.79 (microtubule-associated protein), or TcCLB.506391.30 (EF-hand protein 5) were already described and used as antigens \[[@pntd.0005972.ref020],[@pntd.0005972.ref046]\], this is the first time that their fine mapped epitopes are tested for diagnostic purposes. Other peptides such as p16, p7, p11 and p19 are part of proteins that have been identified as potential antigens \[[@pntd.0005972.ref035]\] but with no other serological evidence before our microarray experiments. Peptide p1, on the other hand, was derived from a member of the Mucin-Associated Surface Protein (MASP) family \[[@pntd.0005972.ref038]\], which is a large family of genes which were shown recently to be the target of the adaptive immune response in an animal model of infection \[[@pntd.0005972.ref058]\]. The MASP protein encoded by gene TcCLB.507071.20 was selected from the genome, as part of an effort to obtain a detailed characterization of the antigenicity and epitopes of this gene family in human infections \[[@pntd.0005972.ref059]\]. Peptide p6 contains a slightly different version of the sequence TTRAPSRLREID, which has been identified as the major and conserved linear B-cell epitope included within the otherwise highly polymorphic TcMUCII family of *T*. *cruzi* proteins \[[@pntd.0005972.ref044],[@pntd.0005972.ref060]\]. Whereas peptide p2 is a novel epitope from a putative 60S ribosomal protein L7a, that we have also previously identified as a potential antigen \[[@pntd.0005972.ref035]\].

Using a panel of Chagas-positive and negative (control) samples, we performed a thorough serological characterization of the selected peptides. This allowed us to obtain a relatively large matrix of ELISA responses for all peptides against individual serum samples. This led us to identify a number of peptides with promising diagnostic potential, such as peptides p1, p7, p11, p16 and p19, which presented sensitivities above 80%, with no false positive responses in the first evaluation using a small panel of 16 sera, and only a few false positive responses (with specificities from 96.5% to 100%) in a second evaluation using a larger panel of sera. These sensitivities are similar to those originally reported in the first characterizations of validated serodiagnostic antigens such as TcD (95% for chronic subjects \[[@pntd.0005972.ref061]\]) and SAPA (10% for chronic subjects, 90% for acute infection \[[@pntd.0005972.ref062]\]), which were later improved when developed into a multiantigen diagnostic reagent (e.g. the Chagatest kit of Wiener Labs that includes these antigens claims a sensitivity of 98.8%\[[@pntd.0005972.ref063]\]). Hence, even if some peptides displayed sensitivities that were not very high when assessed singly, they were high enough as to keep them under consideration for development of an assay based on combinations of peptides.

The matrix of ELISA responses was then used to guide the rational formulation of a multiepitope diagnostic reagent using a well-defined algorithm for the inclusion of peptides. The first combinations tested did not achieve a significantly high performance, even if the theoretical prediction ([Fig 2](#pntd.0005972.g002){ref-type="fig"}) would suggest otherwise. One reason for this is that even though the input to the EpiSelect algorithm included the level of response of each subject against each peptide (represented as the number of standard deviations above negative controls), the effect of combining peptides produced a higher background signal that was not predicted by the algorithm. Another reason was the inclusion in our panel of Chagas-positive sera of several samples with moderately low antibody titers overall (see for example the 9 sera grouped in the bottom branch in [S2 Fig](#pntd.0005972.s002){ref-type="supplementary-material"}). Despite these pitfalls, the detailed data present in this matrix was pivotal in identifying peptides for inclusion in the final multiepitope formulation. The rationale for inclusion of peptides was the ability of a given peptide (as observed in the matrix) to potentially overcome a negative response for a given serum sample. For example, peptides p6 and p2, followed by p11 represented an optimal complement of the two best performing peptides, pc1 (from the antigenic repeat of the CA-2/B13 antigen Ag2) and pc2 (the serodiagnostic epitope TcE) for diagnosis. Also, peptide p13 when combined with peptides pc1 and pc2 was one of the few peptides that provided relatively high signal in the ELISA assay against the group of sera with relatively low overall responses. The fact that we could consistently increase the performance of each combination upon following this rationale shows the usefulness of this approach.

Interestingly, all peptides in the final multiepitope formulation are highly conserved (see [S1 Text](#pntd.0005972.s006){ref-type="supplementary-material"}). A sequence similarity search across available complete genomes (e.g. those from the CL-Brener \[[@pntd.0005972.ref064]\] and Sylvio X10 \[[@pntd.0005972.ref065]\] strains using BLASTP) or from draft assemblies (Tula cl2, Esmeraldo cl3, Dm28c or JRcl4 in the TriTrypDB resource \[[@pntd.0005972.ref066]\], release 30 from February 2017, using TBLASTN) shows that all peptides are highly conserved across strains representing different evolutionary lineages of the parasite (TcI, TcII, TcV, TcVI).

The observed diagnostic performances for all peptides and peptide combinations tested were very promising, particularly considering that all assays were based on short synthetic peptides. Our final best performing multi-epitope combination was based on a combination of seven antigenic peptides. With an equimolar mixing of peptides, we attained a very high (\>96%) level of sensitivity and specificity. These are highly promising values for a first optimization attempt; the final ELISA assay/formulation could be indeed further improved using different blocking reagents, coupled detection system and, most importantly, by adjusting the relative concentration of different peptides in the final mixture.

Analysis of potential cross-reactivity with other co-endemic diseases and pathogens is essential to validate any diagnostic reagent. In the case of Chagas Disease, cross-reactivity against infections with Leishmania species is a particular concern \[[@pntd.0005972.ref067]\]. We have included a panel of serum samples from confirmed cases of tegumentary leishmaniasis from the northern province of Salta, Argentina to assess the performance of our formulation. This also gave us the opportunity to improve the assessment of specificity by analizing a paired set of negative (control) samples (chagas-negative and leishmaniasis-negative) from the same endemic region. From a set of 37 of these samples which were negative for Chagas Disease, only one gave a positive cross-reactive response ([Fig 3](#pntd.0005972.g003){ref-type="fig"}). Although this highlights the need to perform a more extensive characterization of this cross-reactive sample (e.g. against our complete panel of peptides), and eventually revise the combination of peptides in our formulation, the current multiepitope assay has a sufficiently high specificity at this stage (99.15%), comparable to other commercially available kits \[[@pntd.0005972.ref063]\] that can certainly be improved by optimization of the assay or by replacing of cross-reactive peptides.

Besides the obvious attention to the diagnostic performance of the identified peptides, these results serve to validate the use of high-density peptide microarrays as a fast screening platform. The fact that all selected peptides gave positive responses against several Chagas-positive subjects show that this technology can be trusted to rapidly identify and map epitopes of complex pathogens. It is also worth mentioning here that there are about a hundred additional antigenic regions within the signal range observed in the peptide microarray screening from which these peptides were identified \[[@pntd.0005972.ref036]\] and that await further serological characterization. This observation, together with the fact that the microarray screening only covered \~3% of the parasite proteome, show that there is still a large repertoire of Chagas-specific antibody specificities that remain serologically unexplored.

The results presented herein hence provide a novel, robust multi-epitope formulation as a basis for the development of improved peptide-based serodiagnostics for Chagas Disease. In contrast with chimeric DNA constructs that encode multiepitope recombinant proteins, the fact that this diagnostic reagent is based on the combination of short peptides that can be synthesized separately and easily formulated in a mix-and-match approach, means that it can be improved successively over time with only a reasonable effort.

Supporting information {#sec013}
======================

###### Antibody binding profiles of antigens showing the location of selected peptides.

The antibody binding profiles of antigens were derived from previously published data \[[@pntd.0005972.ref036]\](ArrayExpress accession number E-MTAB-3008). Briefly, high-density peptide microarray slides were assayed with purified immunoglobulins from healthy subjects (four pools of samples labeled A-D, shown as dashed lines) or Chagas positive subjects (four pools of samples labeled A-D, shown as solid lines). Antibody binding profiles were reconstructed for each of the selected antigens as described previously. Each plot in the figure shows the normalized and smoothed signal profile for a single antigen (one per page). A different scale may be used in each plot to best accommodate all peaks. The location of each the selected peptides used in this study is shown in context with other antigenic regions in each antigen. File: S1 Fig.

(PDF)

###### 

Click here for additional data file.

###### Heatmap plot showing the pattern of reactivity of peptides against a panel of positive sera.

Heatmap display of ELISA reactivity of each of the 27 peptides tested against a panel of 62 positive sera samples. For the heatmap display the reactivity values (in the form of z-scores above background) were transformed for clarity using a sigmoid function centered around 3. Peptides and subjects were clustered using a hierarchical clustering algorithm (R, hclust). A group of subjects showing moderately low ELISA reactivity across peptides has been highlighted (see main text). File: S2 Fig.

(PDF)

###### 

Click here for additional data file.

###### STARD flow diagram for studies reporting diagnostic accuracy.

(PDF)

###### 

Click here for additional data file.

###### Detailed results of ELISA assays.

The spreadsheet workbook file contains a number of worksheets with results from different ELISA assays: 1) all vs all ELISA results (N = negative; P = positive) for each of the 27 peptides against 62 sera samples from chronically infected (Chagas-positive) patients and 16 negative controls (healthy subject); 2) all vs all (z-scores) contains the input matrix for the EpiSelect algorithm; 3) additional negative sera, ELISA results for the best performing 16 peptides against an additional panel of 61 negative sera samples; 4) Formulation 1, ELISA results for the combination of peptides {pc1, pc2, pc3, p6, p13}; 5) Formulation 2, ELISA results for the combination of peptides {pc1, pc2, p6, p7, p24}; 5) Final formulation, ELISA results for the combination of peptides {pc1, pc2, pc3, p6, p7, p13, p24}. File: S1 Table.

(XLSX)

###### 

Click here for additional data file.

###### STARD checklist for studies reporting diagnostic accuracy.

(PDF)

###### 

Click here for additional data file.

###### Conservation of peptides and epitopes across evolutionary Trypanosoma cruzi evolutionary lineages.

This supporting file contains information on the conservation of the selected epitopes. We have tried to compile information from complete *T. cruzi* genomes from different evolutionary lineages (Discrete Typing Units, DTUs). For each peptide (naming/numbering follows [Table 1](#pntd.0005972.t001){ref-type="table"}), we provide a small multiple sequence alignment showing presence and conservation of the peptide in other strains/isolates. In the case of hybrid lineages more than one representative sequence may have been included in the alignment. File: S1 Text.

(TXT)

###### 

Click here for additional data file.
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